GlassScriptPhysician profile
Lane C Peterson
NPI 1992711766
$4,608.32
in general payments reported to CMS, 2019-2025
31 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $182 · 2021: $401 · 2022: $408 · 2023: $586 · 2024: $1,161 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088 · Travel and Lodging: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.55 |
| Travel and Lodging | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $818.07 | 2023-2024 | Mild Device Kit |
| Boston Scientific Corporation | $757.17 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Abbott Laboratories | $637.01 | 2021-2025 | Proclaim, Axium |
| Medtronic, INC. | $410.44 | 2021-2025 | Intellis Adaptivestim |
| Tersera Therapeutics LLC | $248.11 | 2019-2020 | |
| Daiichi Sankyo INC. | $229.35 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.76 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $171.30 | 2019-2023 | Ztlido |
| Abbvie INC. | $149.97 | 2023-2024 | |
| Pfizer INC. | $129.96 | 2019-2025 | |
| Nevro Corp. | $123.96 | 2020-2024 | Senza |
| Globus Medical, INC. | $122.40 | 2025 | Senza |
| Spr Therapeutics, INC | $105.38 | 2019-2025 | Sprint Pns System |
| Merit Medical Systems INC | $70.27 | 2021-2024 | Stabilit System |
| Amgen INC. | $48.78 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $46.47 | 2019-2023 | Belbuca |
| Novartis Pharmaceuticals Corporation | $38.01 | 2020-2021 | |
| Sentynl Therapeutics, INC. | $37.02 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $33.54 | 2020-2021 | |
| Stimwave Technologies Incorporated | $26.94 | 2021 | |
| Zimmer Biomet Holdings, INC. | $25.52 | 2019-2020 | |
| Si-Bone, INC. | $23.46 | 2024 | |
| Shionogi INC | $22.55 | 2019 | |
| Nalu Medical, INC. | $22.17 | 2025 | Nalu Neurostimulation System |
| Convatec INC. | $19.47 | 2025 | |
| Averitas Pharma INC. | $18.47 | 2023 | Qutenza |
| Ultragenyx Pharmaceutical INC. | $15.79 | 2019 | |
| Stryker Corporation | $14.52 | 2024 | Mild Device Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $14.05 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.33 | 2023 | Seglentis |
| Arbor Pharmaceuticals, INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lane Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.